906 followers
New article: Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis https://t.co/pJe2XWxLBR #livercancer #oncology https://t.co/q9thLEeytq
New article: Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis https://t.co/pJe2XWxLBR #livercancer #oncology https://t.co/q9thLEeytq